CNM-Au8 May Be Source of Motor Neuron Gains Being Seen in Phase 2 Trial

CNM-Au8 May Be Source of Motor Neuron Gains Being Seen in Phase 2 Trial

282270

CNM-Au8 May Be Source of Motor Neuron Gains Being Seen in Phase 2 Trial

Nearly half of all patients in a Phase 2 trial of CNM-Au8, Clene Nanomedicine’s lead candidate for the treatment of amyotrophic lateral sclerosis (ALS), showed improvements in the health and functioning of their motor neurons, according to the interim trial data. These data are still blinded, meaning it’s unknown at this point if these benefits are in patients using the investigative oral therapy or those on a placebo in the RESCUE-ALS (NCT04098406) clinical trial. But if CNM-Au8 is…

You must be logged in to read/download the full post.